Presentation at the Lancet Summit on GeNeuro’s new anti-HERV-K antibody for amyotrophic lateral sclerosis
GENEVA–(COMMERCIAL THREAD) – Regulatory news:
GeNeuro (Paris: GNRO) (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, today announced that its Scientific Director, Dr HervÃ© Perron, unveiled today ‘ hui at “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” additional findings from the Amyotrophic Lateral Sclerosis (ALS) Preclinical Research Program developed in partnership with the National Institute of Neurological Disorders and Stroke (NINDS), which is part from the United States National Institutes of Health (NIH).
“This joint NINDS / GeNeuro study showed the specific and effective inhibition of the neurotoxic effects of HERV-K ENV from the extracellular medium in vitro and in vivo, using the anti HERV-K K01 monoclonal antibody from GeNeuro,” noted Dr HervÃ© Perron, Scientific Director of GeNeuro.
“A new pathogenic mechanism has been unveiled and characterized, and these results open up new perspectives for a therapeutic intervention against sporadic ALS â, said Dr Avindra Nath, clinical director of the National Institute of Neurological Disorders and Stroke, who heads the joint NINDS / GeNeuro ALS research program.
These results, following those presented by Dr. Avindra Nath at the American Neurological Association (ANA) annual meeting on October 17, 2021, show in vitro and in vivo the neurotoxic effects specifically mediated by HERV-K ENV, a retroviral envelope protein encoded by a pathogenic member of the HERV-K family of endogenous human retroviruses (HERV-K ENV protein). More importantly, they confirm the neutralizing effects of the novel anti-HERV-K monoclonal antibody specific for GeNeuro.
As previously mentioned, GeNeuro’s preclinical development program has enabled its anti-HERV-K ENV antibody to now be humanized and ready to go into GMP manufacturing. The program could start clinical trials as early as 2022.
“These results confirm the potentially key role of HERV-K ENV in ALS and the potential of the new GeNeuro antibody in this indication.,” noted JesÃºs Martin-Garcia, CEO of GeNeuro. “We will now seek partnerships to bring this product to patients as quickly as possible.”
The presentation is available on GeNeuro’s Youtube channel.
Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease or clinically motor neuron disease, is a fatal and rapidly progressive neurodegenerative disease characterized by loss of motor neurons leading to progressive muscle paralysis. The incidence of ALS is approximately 5 per 100,000 people in the United States, 1 in 3 per 100,000 people worldwide, and is constant in various populations.
GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing the causal factors encoded by HERVs, which make up 8% of human DNA. .
GeNeuro is based in Geneva, Switzerland, and has R&D facilities in Lyon, France. It owns the rights to 17 patent families protecting its technology.
For more information visit: www.geneuro.com
This press release contains certain forward-looking statements and estimates concerning the financial condition, results of operations, strategy, plans and future performance of GeNeuro and the markets in which it operates. These forward-looking statements and estimates may be identified by words such as “anticipate”, “believe”, “may”, “could”, “estimate”, “expect”, “intend”, “is intended to” for “,” “may”, “could”, “plan”, “potential”, “foresee”, “objective”, “should”, or the negative of these and other similar expressions. They integrate all the subjects which are not historical facts. Forward-looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were considered reasonable at the time they were made, but which may prove to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the control of the business. Consequently, the actual results, the financial situation, the performances and / or the achievements of GeNeuro or of the industry may turn out to be materially different from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. . Due to these uncertainties, no representation is made as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates are only valid on the date on which they are made, and GeNeuro does not undertake to update or revise them, whether as a result of new information, future events or otherwise, unless required by law.